pubmed-article:20179215 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20179215 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:20179215 | lifeskim:mentions | umls-concept:C1414864 | lld:lifeskim |
pubmed-article:20179215 | lifeskim:mentions | umls-concept:C1522480 | lld:lifeskim |
pubmed-article:20179215 | lifeskim:mentions | umls-concept:C1427801 | lld:lifeskim |
pubmed-article:20179215 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
pubmed-article:20179215 | lifeskim:mentions | umls-concept:C0021044 | lld:lifeskim |
pubmed-article:20179215 | lifeskim:mentions | umls-concept:C1516048 | lld:lifeskim |
pubmed-article:20179215 | lifeskim:mentions | umls-concept:C1510438 | lld:lifeskim |
pubmed-article:20179215 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:20179215 | pubmed:dateCreated | 2010-3-2 | lld:pubmed |
pubmed-article:20179215 | pubmed:abstractText | In vitro sensitivity to the proapoptotic receptor agonists dulanermin (rhApo2L/TRAIL) and drozitumab (DR5-agonist antibody) is strongly predicted by the expression of the O-glycosylation enzymes GALNT14 in non-small cell lung cancer (NSCLC) cell lines (among others) and of FUT3/6 in colorectal cancer (CRC) cell lines. We developed immunohistochemistry (IHC) assays that measure GALNT14 and FUT3/6 levels in archival formalin-fixed, paraffin-embedded human tumor tissue to determine marker prevalence in NSCLC and CRC tissue and to enable the future examination of these markers in clinical trials. | lld:pubmed |
pubmed-article:20179215 | pubmed:language | eng | lld:pubmed |
pubmed-article:20179215 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:20179215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20179215 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20179215 | pubmed:month | Mar | lld:pubmed |
pubmed-article:20179215 | pubmed:issn | 1078-0432 | lld:pubmed |
pubmed-article:20179215 | pubmed:author | pubmed-author:WagnerKlausK | lld:pubmed |
pubmed-article:20179215 | pubmed:author | pubmed-author:AshkenaziAviA | lld:pubmed |
pubmed-article:20179215 | pubmed:author | pubmed-author:SternHoward... | lld:pubmed |
pubmed-article:20179215 | pubmed:author | pubmed-author:AmlerLukasL | lld:pubmed |
pubmed-article:20179215 | pubmed:author | pubmed-author:PadillaMaryM | lld:pubmed |
pubmed-article:20179215 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:20179215 | pubmed:day | 1 | lld:pubmed |
pubmed-article:20179215 | pubmed:volume | 16 | lld:pubmed |
pubmed-article:20179215 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20179215 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20179215 | pubmed:pagination | 1587-96 | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:meshHeading | pubmed-meshheading:20179215... | lld:pubmed |
pubmed-article:20179215 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20179215 | pubmed:articleTitle | Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. | lld:pubmed |
pubmed-article:20179215 | pubmed:affiliation | Departments of Research Pathology, Development Oncology Diagnostics, and Molecular Oncology, Genentech, Inc, South San Francisco, California, USA. | lld:pubmed |
pubmed-article:20179215 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:20179215 | pubmed:publicationType | Validation Studies | lld:pubmed |
entrez-gene:2525 | entrezgene:pubmed | pubmed-article:20179215 | lld:entrezgene |
entrez-gene:2528 | entrezgene:pubmed | pubmed-article:20179215 | lld:entrezgene |
entrez-gene:79623 | entrezgene:pubmed | pubmed-article:20179215 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20179215 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20179215 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20179215 | lld:entrezgene |